Guidance Development: An Update for Statisticians
*Steve Wilson, FDA 


Each year FDA publishes guidance on the development and review of new drug and biologic products. This roundtable will be an opportunity for us to learn about, think about and discuss how this new guidance (draft and final, from clinical trial design to electronic submission and review) might influence the work of industry and agency statisticians.